Legal professionals, especially those practicing in pharmaceutical patent litigation, will be heading to Chicago on October 24th and 25th for the 9th Annual Paragraph IV Disputes Master Symposium.
This symposium gathers experts in trademark and patent law for brand-name and generic drug companies. It provides an opportunity for legal professionals to receive real-time updates on significant developments within Hatch-Waxman litigation.
The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act of 1984, greatly impacts pharmaceutical patent practices. The Act’s mission is to maintain a balanced competitive marketplace between brand-name drug manufacturers and generic counterparts.
Not only are there updates on relevant legal developments, but the symposium also provides a valuable opportunity for peer-to-peer networking within the industry. This ability to connect and collaborate with other like-minded professionals is just one of the many benefits attendees can gain from participating in this event.
Organized by the American Conference Institute (ACI), the symposium annually serves as a significant touchstone for associates, partners, in-house counsel, and other pharmaceutical industry stakeholders. It frames the pathway forward in what is a continually evolving and intricately complex field of patent litigation.
Knowledge sharing and industry engagement have proven invaluable in informing business strategy and legal practice. The Paragraph IV Disputes Master Symposium does an admirable job of providing a venue for such twin goals to occur.